#Non-steroidal Anti-inflammatory Drugs Market Share

[spermarket]

Non-steroidal Anti-inflammatory Drugs Market Trends, Share, Revenue, Outlook and Future Opportunities: SPER Market Research

Non-steroidal anti-inflammatory medications are often used to treat pain, inflammation, and fever. They are commonly used to relieve arthritis, muscle aches, headaches, menstrual cramps, and minor injuries such as sprains and strains. NSAIDs inhibit the formation of substances called prostaglandins in the body, which are responsible for pain and inflammation. 

These drugs, such as ibuprofen (Advil, Motrin) and naproxen (Aleve), are frequently available in over-the-counter and prescription strength formulations. NSAIDs are often taken orally, however some can be used topically as creams or gels to alleviate localized pain. 

According to SPER market research, ‘Global Non-steroidal Anti-inflammatory Drugs Market Size- By Disease Indication, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Non-steroidal Anti-inflammatory Drugs Market is predicted to reach 40.44 billion by 2034 with a CAGR of 5.92%. 

Drivers: 

The NSAIDs market is expanding rapidly because to the increasing prevalence of chronic pain and inflammatory disorders such as arthritis and migraines. This demand is being driven by an increasing senior population, which is more sensitive to these illnesses, as well as a growing preference for NSAIDs due to their lower side effect profile when compared to alternative pain medicines. Furthermore, the market is being bolstered by an increase in medicinal approvals, new product launches, and increased R&D activity. 

Request a Free Sample Report: https://www.sperresearch.com/report-store/non-steroidal-anti-inflammatory-drugs-market.aspx?sample=1

Restraints: 

The broad use of NSAIDs is limited by the possibility of major side effects such as cardiovascular events, gastrointestinal issues, renal failure, and hypersensitivity responses. Despite the relatively low individual risk for each patient, the cumulative usage of NSAIDs throughout populations increases the overall risk of adverse effects. This needs a rigorous review of individual patient risk factors before to prescribing NSAIDs, limiting the growth of the anti-inflammatory medications industry. Healthcare practitioners must weigh the therapeutic benefits of NSAIDs against the dangers they pose in order to ensure patient safety and regulatory compliance in clinical practice. 

North America dominated the global non-steroidal anti-inflammatory medicines industry, accounting for a sizable revenue share in 2024; the sector is predicted to develop significantly, affected by a number of major variables. A vast number of manufacturers and prominent companies' strategic endeavors are driving market growth. Some significant market players are Pfizer Inc, Bayer AG, GSK plc, Dr. Reddy’s Laboratories Ltd, Viatris Inc, Teva Pharmaceutical Industries Ltd, Johnson and Johnson Services, Merck & Co, Inc. and others.

For More Information, refer to below link: –  

Non-steroidal Anti-inflammatory Drugs Market Growth

Related Reports:  

Clinical Nutrition for Diabetes Care Market Growth, Size, Trends Analysis - By Product, By Stage, By Sales Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Cold Pain Therapy Market Growth, Size, Trends Analysis - By Product, By Application, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Follow Us – 

LinkedIn | Instagram | Facebook | Twitter

Contact Us: 

Sara Lopes, Business Consultant — USA 

SPER Market Research 

enquiries@sperresearch.com 

+1–347–460–2899

[wellnesstribe]

Arthritis Therapeutics Market Insights: Overcoming Challenges and Expanding Global Market Access

The global arthritis therapeutics market is poised for steady growth due to the rising incidence of arthritis and advancements in treatment options. Arthritis, which encompasses a range of inflammatory joint diseases, including osteoarthritis, rheumatoid arthritis, and psoriatic arthritis, affects millions of individuals worldwide. As the global population ages, the demand for effective therapies and treatments is escalating, thus driving the market forward.

Market Overview

Arthritis is one of the most prevalent chronic conditions globally, especially in aging populations. According to the World Health Organization (WHO), the prevalence of arthritis is expected to increase as the global demographic structure shifts toward older age groups. With a substantial rise in cases, there is an increasing demand for arthritis therapeutics that can manage symptoms, slow disease progression, and improve quality of life. This has led to the development of new treatment approaches, from non-steroidal anti-inflammatory drugs (NSAIDs) to biological treatments and advanced biologic therapies like monoclonal antibodies.

Key Market Drivers

Growing Aging Population: The most significant driver for the arthritis therapeutics market is the growing geriatric population. As people age, the risk of developing arthritis increases, creating a rising need for long-term treatment solutions.

Increasing Arthritis Prevalence: A sedentary lifestyle, obesity, and rising awareness of the condition have significantly increased the number of people diagnosed with arthritis, particularly osteoarthritis and rheumatoid arthritis.

Advancements in Drug Development: Innovations in biologics and personalized medicine have revolutionized arthritis treatment options. Newer therapies, including disease-modifying antirheumatic drugs (DMARDs) and biologic agents, provide effective relief from symptoms and slow the progression of the disease.

Improvement in Healthcare Infrastructure: As healthcare systems improve globally, particularly in developing economies, access to arthritis treatments is expanding. This has facilitated market growth, especially in emerging regions.

Market Challenges

Despite the growth prospects, the arthritis therapeutics market faces several challenges. High treatment costs, especially for biologics, remain a significant barrier to widespread adoption, particularly in low-income countries. Additionally, the potential side effects of advanced therapies can discourage patients from pursuing long-term treatments. There is also a gap in the accessibility of affordable medications in underdeveloped regions, which hinders market growth.

Moreover, the treatment of arthritis requires a multifaceted approach. While pharmacological treatments are essential, lifestyle changes such as regular physical activity, a healthy diet, and weight management are critical to managing the condition. The need for holistic management is pushing the market to not only focus on drug development but also on integrated care solutions that involve physiotherapy and patient education.

Regional Insights

The North American region holds the largest market share in arthritis therapeutics due to advanced healthcare infrastructure and higher healthcare spending. The U.S. leads the market with its well-established pharmaceutical industry and high demand for biologic drugs.

Europe follows closely, with the UK, Germany, and France being key contributors. The European market is expanding, especially with the growing aging population and increasing healthcare investments. However, the affordability of treatments remains a concern in some countries.

Emerging markets in Asia-Pacific and Latin America are also experiencing significant growth. With rising healthcare awareness and improved access to healthcare services, countries like China, India, and Brazil are contributing to the growing demand for arthritis therapies.

Competitive Landscape

The arthritis therapeutics market is highly competitive, with several major players investing in new therapies. Companies such as Pfizer, AbbVie, Roche, Johnson & Johnson, and Novartis dominate the market. These companies are focusing on research and development to bring innovative treatments to market, particularly biologic drugs and biosimilars, which are expected to grow significantly in the coming years.

In addition, there is a rising trend of partnerships and collaborations between pharmaceutical companies, biotechnology firms, and research institutions. These collaborations aim to accelerate drug development and enhance the therapeutic options available to patients.

Future Outlook

The future of the arthritis therapeutics market looks promising with increasing awareness, advancements in medical research, and an aging global population. The shift toward biologic therapies and personalized medicine is expected to be a game-changer in the treatment of arthritis. Moreover, the market is witnessing an increasing demand for affordable and effective treatment options, driving pharmaceutical companies to explore novel treatment paradigms.

Conclusion

In conclusion, the arthritis therapeutics market is experiencing rapid expansion, driven by demographic trends, technological advancements, and growing awareness. While challenges like affordability and accessibility persist, ongoing developments in drug discovery and healthcare infrastructure improvements are poised to transform the treatment landscape. As the market grows, it offers significant opportunities for pharmaceutical companies to expand their product offerings and improve patient outcomes worldwide.

[metatechinsights]

Pet Arthritis Market Size, Share & Growth Forecast 2025-2035

Industry Outlook

The Pet Arthritis market accounted for USD 3.53 Billion in 2024 and is expected to reach USD 8.15 Billion by 2035, growing at a CAGR of around 7.9% between 2025 and 2035. The Pet Arthritis Market focuses on the diagnosis, treatment, and management of arthritis in pets, fundamentally dogs and cats. This sector incorporates a variety of products such as medications, dietary supplements, therapeutic devices, and alternative treatments outlined to lighten joint pain and improve mobility. With the expanding life span of pets and a developing awareness of animal wellbeing, this market is extending quickly. Key players are presenting innovative solutions, such as natural supplements and regenerative treatments, catering to the rising demand for effective and holistic treatment alternatives. The market moreover reflects the trend of pet humanization, where owners seek quality care for their aging pets. 

Report Scope:

2024

2035Market Size in 2024 & 203510.008.006.004.002.000.0020242035ParameterDetailsLargest MarketNorth AmericaFastest Growing MarketAsia PacificBase Year2024Market Size in 2024USD 3.53 BillionCAGR (2025-2035)7.9%Forecast Years2025-2035Historical Data2018-2024Market Size in 2035USD 8.15 BillionCountries CoveredU.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, Switzerland, Sweden, Finland, Netherlands, Poland, Russia, China, India, Australia, Japan, South Korea, Singapore, Indonesia, Malaysia, Philippines, Brazil, Argentina, GCC Countries, and South AfricaWhat We CoverMarket growth drivers, restraints, opportunities, Porter’s five forces analysis, PESTLE analysis, value chain analysis, regulatory landscape, pricing analysis by segments and region, company market share analysis, and over 10 companiesSegments CoveredProduct Type, Pet Type, Route of Administration, Distribution Channel and Region

To explore in-depth analysis in this report - Request Free Sample Report

Market Dynamics

Rising demand for natural and alternative arthritis treatments is driving market growth

The rising demand for natural and alternative arthritis medications is basically driving growth in the Pet Arthritis Market as pet owners dynamically look for holistic choices for directing their pets' wellbeing. Concerns around the side impacts of traditional medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), have driven various owners to examine more normal cures. A overview conducted by the American Pet Products Association (APPA) indicates that 45% of pet owners prefer natural products when considering their pets' prosperity and wellness. This move towards characteristic arrangements isn't as it were driven by the need to avoid potential adverse effects but additionally reflects a developing awareness of the benefits of holistic care for improving the quality of life in maturing pets.

In addition, the market for natural supplements is encountering quick improvement, with a wide amplify of products focused on joint health and generally well-being getting to be progressively accessible. The National Animal Supplement Council (NASC) detailed that the pet supplement industry has created significantly over the past few years, reaching over $1.2 billion in 2022, with joint health products being a key segment. Also, a study published in the Journal of the American Veterinary Medical Association found that 60% of pet owners are willing to consider alternative treatments, such as herbal supplements and acupuncture, for arthritis management. This assembly of components underscores a critical move in customer behavior, driving the improvement of the Pet Arthritis Market towards more normal and alternative treatment options. 

High costs of arthritis treatments limit accessibility for many pet owners.

High costs associated with arthritis treatments pose a significant restraint on the Pet Arthritis Market, limiting availability for many pet owners. Advanced treatment choices, including surgical medications and long-term medicine regimens, can become restrictively costly. According to the American Pet Products Association (APPA), around 40% of pet owners report that cost is a major obstruction to getting to necessary veterinary care. This financial burden can lead to delayed treatment or the deserting of care inside and out, which negatively impacts the quality of life for pets enduring from arthritis.

Besides, pet insurance coverage for arthritis treatments is frequently lacking, assist exacerbating the issue. A study by the North American Pet Health Insurance Association (NAPHIA) shows that only about 30% of pets are insured, and numerous policies don't cover long-term or chronic conditions like arthritis. This need of coverage strengths pet owners to pay out-of-pocket, driving to intense choices about their pets' healthcare. As a result, the high costs of treatment not only confine get to to effective care but also highlight the require for more reasonable and available choices in the Pet Arthritis Market. 

Innovations in treatment modalities are introducing new, non-invasive options for managing pet arthritis.

Innovations in treatment modalities are significantly driving growth in the Pet Arthritis Market by introducing new, non-invasive options for managing arthritis in pets. Advances in veterinary medication have driven to the improvement of inventive treatments such as laser treatment, hydrotherapy, and regenerative medications like platelet-rich plasma (PRP) therapy and stem cell treatment. These non-invasive strategies not only reduce the distress related with traditional treatments but moreover advance faster recovery times and progressed generally health. According to a study published in the Journal of the American Veterinary Medical Association, about 70% of veterinarians report positive results in arthritis management when utilizing these progressed treatment options, indicating a move in how pet arthritis is approached.

Moreover, the developing acceptance and integration of innovation in veterinary care have improved the viability of these developments. For occurrence, veterinary telemedicine is gaining traction, permitting pet owners to consult with masters remotely and get to innovative medications without the require for obtrusive methods. A report by the American Veterinary Medical Association (AVMA) indicates that telehealth utilize in veterinary practice has expanded by over 30% in later years. This mechanical advancement not only makes care more accessible but also allows for personalized treatment plans tailored to individual pets' needs. The rise of imaginative, non-invasive treatment modalities is reshaping the Pet Arthritis Market, offering pet owners successful arrangements that improve their pets' quality of life whereas reducing the risks related with traditional treatments.

Industry Experts Opinion

“I was excited to participate as a clinical investigator in the Zenrelia field study because it is clear we need more treatment options for itchy dogs,"

-  Dr. Tom Lewis, veterinarian and founder of Dermatology for Animals

 “We’ve seen how this has really taken off in the human health space in the past few decades, and we have just begun to see the positive impact that biological therapies can have in the animal health space. We definitely see a bright future for this.”

- Dirk E. Polzer, the Chief Medical Officer (CMO) at Elanco Animal Health

Segment Analysis

Based on product type, the Pet Arthritis Market is divided into Medications, Assistive Devices and Alternative Therapies, Nutritional Supplements, and Others. The Medications segment contains NSAIDs and corticosteroids, Then Assistive Devices feature joint braces and mobility aids. The Alternative Therapies having treatments like acupuncture & laser therapy, and Nutritional Supplements encompass products with glucosamine and omega-3 fatty acids. The Others category covers additional products and services for managing pet arthritis.

You can also buy individual sections of this report.

Would you like to review the price list for each section?

Request Sectional Data

[healthcarefuture]

Analyzing the Competitive Landscape of the Eczema Treatment Market

Eczema, also known as atopic dermatitis, is a common, chronic skin condition that causes inflammation, redness, and itching. People with eczema often experience flare-ups, which can significantly impact their quality of life. As the prevalence of eczema increases worldwide, there is a growing demand for effective treatments. Eczema Therapeutics includes a range of options such as topical steroids, non-steroidal anti-inflammatory creams, biologics, and lifestyle modifications. The Eczema Therapeutics market has shown substantial growth, fueled by increasing awareness, technological advancements in treatments, and a rising number of clinical trials focused on finding more effective therapies.

In 2022, the market size for eczema treatments was projected to be 9.44 billion USD. By 2032, the eczema therapeutics market is projected to have grown from 9.93 billion USD in 2023 to 15.7 billion USD. During the 2024–2032 forecast period, the Eczema Therapeutics Market is anticipated to increase at a CAGR of around 5.22%.

Eczema Therapeutics Size and Share

The Eczema Therapeutics market has expanded significantly, driven by a growing patient base and ongoing research efforts. In recent years, the market size for Eczema Therapeutics has witnessed a compound annual growth rate (CAGR) that reflects both increased demand and innovation. Eczema Therapeutics share is primarily distributed across major pharmaceutical companies investing in the development of biologic drugs, topical treatments, and other advanced options. With significant progress in drug approvals and new players entering the market, the Eczema Therapeutics share is expected to diversify further, creating opportunities for both existing and emerging companies.

Eczema Therapeutics Analysis

In-depth analysis of the Eczema Therapeutics market reveals that treatment options are becoming more personalized and effective. Conventional topical treatments remain widely used due to their accessibility and cost-effectiveness. However, biologics and other advanced therapeutics are gaining popularity for their targeted mechanisms, which can reduce side effects and improve patient outcomes. Eczema Therapeutics analysis highlights the growing preference for therapies with a strong safety profile and long-lasting efficacy. Additionally, the analysis shows that unmet needs for pediatric eczema treatments are driving research and development (R&D) efforts, as younger patients represent a large portion of the affected population.

Eczema Therapeutics Trends

Emerging Eczema Therapeutics trends include the rise of biologic drugs, which target specific pathways involved in the immune response, providing relief to patients who do not respond to traditional treatments. Another key trend is the development of non-steroidal topical options, which cater to patients seeking alternatives to steroids due to concerns about side effects. Digital health tools, such as mobile apps and wearables, are also being integrated to support remote monitoring and management of eczema symptoms, reflecting an increased emphasis on personalized care. Eczema Therapeutics trends additionally show a shift toward over-the-counter options and holistic approaches, including dietary adjustments and lifestyle changes, which are gaining traction among patients looking for natural and complementary therapies.

Reasons to Buy Eczema Therapeutics Reports

Comprehensive Market Insights: The report provides an in-depth look at the Eczema Therapeutics market, covering its size, share, trends, and analysis. This is valuable for stakeholders looking to make informed investment and business decisions.

Detailed Competitive Landscape: With detailed information on major players and their strategies, the report helps stakeholders understand competitive positioning in the Eczema Therapeutics market.

Identification of Growth Opportunities: Buyers gain insight into emerging segments and trends in Eczema Therapeutics, enabling them to leverage new opportunities for growth and innovation.

R&D and Innovation Focus: The report sheds light on recent research, development activities, and technological advances, crucial for companies seeking to stay ahead in the Eczema Therapeutics market.

Market Forecast and Projections: Detailed forecasts help stakeholders plan for future developments, ensuring they stay updated with upcoming market changes and potential demand fluctuations.

Recent Developments in Eczema Therapeutics

Recent developments in Eczema Therapeutics include FDA approval of novel biologic drugs that offer targeted relief for patients with moderate to severe eczema. These biologics represent a breakthrough for patients who have not found success with conventional treatments. Another significant advancement is the increased focus on gene therapy, with several companies conducting clinical trials exploring genetic approaches to managing eczema. Additionally, new non-steroidal topical treatments have entered the market, offering alternatives for those seeking to minimize steroid exposure. Digital health integration, with mobile applications for symptom tracking, is also on the rise, supporting both patients and healthcare providers in better managing eczema. Finally, several pharmaceutical companies have announced collaborations aimed at developing next-generation eczema treatments, signaling ongoing investment in innovation within the Eczema Therapeutics market.

Related reports:

medical kiosk market

molecular quality control market

next generation solar cell market

non invasive aesthetic treatment market

Top of Form

Bottom of Form

[spookysaladchaos]

Global Top 10 Companies Accounted for 73% of total Celecoxib API market (QYResearch, 2021)

Celecoxib API refers to the active pharmaceutical ingredient (API) of the drug Celecoxib, which is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, inflammation, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

The Celecoxib API is the chemical compound responsible for the therapeutic effects of the drug. It is a selective cyclooxygenase-2 (COX-2) inhibitor, which means it works by blocking the production of prostaglandins, which are chemicals produced by the body in response to injury or inflammation. By reducing the production of prostaglandins, Celecoxib can help relieve pain, reduce inflammation, and improve joint mobility.

The Celecoxib API is typically manufactured by pharmaceutical companies in accordance with strict quality control standards to ensure its purity, potency, and safety. It is then used to produce finished dosage forms of Celecoxib, such as tablets or capsules, which are prescribed by healthcare professionals to treat various inflammatory conditions.

According to the new market research report “Global Celecoxib API Market Report 2023-2029”, published by QYResearch, the global Celecoxib API market size is projected to reach USD 0.08 billion by 2029, at a CAGR of 4.9% during the forecast period.

Figure.   Global Celecoxib API Market Size (US$ Million), 2018-2029

Figure.   Global Celecoxib API Top 10 Players Ranking and Market Share (Ranking is based on the revenue of 2022, continually updated)

The global key manufacturers of Celecoxib API include Pfizer, Jiangxi Synergy, ScinoPharm, Jiangsu Chiatai Qingjiang, Jiangsu Hengrui Medicine, Teva Pharmaceuticals, Viatris(Mylan), Aurobindo Pharma, Hisun Pharmaceutical Nantong, Punjab Chemicals, etc.

In 2022, the global top five players had a share approximately 73.0% in terms of revenue.

About QYResearch

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

For more information, please contact the following e-mail address:

Email: global@qyresearch.com

Website: https://www.qyresearch.com

[industryforecastnews]

U.S. Veterinary Orthopedic Medicine Market Size, Share & Growth Analysis Report, 2030

U.S. Veterinary Orthopedic Medicine Market Growth & Trends

The U.S. veterinary orthopedic medicine market size is expected to reach USD 814.51 million by 2030, registering a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing pet population, adoption of pet insurance, rising prevalence of diseases among animals, and advancements in veterinary medicine.

For instance, in October 2023, the FDA approved Librela (bedinvetmab injection), making it the first monoclonal antibody for treating osteoarthritis-related pain in dogs. In addition, in April 2022, American Regent Animal Health, a division of American Regent, Inc., received FDA approval to extend the shelf life of Adequan Canine and Adequan i.m. The expiration date for both products was increased from 24 months to 36 months from the date of manufacture.

Key players in the veterinary orthopedic medicine market are engaging in strategic initiatives like product launches, collaborations, and acquisitions to make their market presence more prominent, impelling market growth. In September 2022, Zoetis acquired Jurox, a private animal health company specializing in veterinary medicines for livestock and companion animals. The deal, finalized in August 2021, included Jurox's operations in Australia and regional offices in the U.S., Canada, and the UK. Such initiatives are anticipated to drive market growth.

For instance, in October 2023, Athersys, Inc. (ATHX), a cell therapy and regenerative medicine company, entered into a licensing agreement with Ardent Animal Health. With this move, Athersys, known for its work with MultiStem (invimestrocel) in critical care, entered the field of animal health. This collaboration with Ardent, a veterinary biotech firm specializing in regenerative medicine and cancer therapies for animals, highlights Athersys’ commitment to advancing veterinary care.    

Some key impacts of the pandemic and respective lockdowns on the market include dampened growth, decreased sales, supply chain disruptions, and operational challenges. However, the pandemic also propelled concerns over animal health and welfare, strengthened the pet parent and animal bond, and increased pet adoption. Moreover, the market witnessed an improved medicalization rate, pet expenditure, and adoption of pet insurance.

Increasing pet humanization and improved diagnostic rates were other positive impacts of the COVID-19 pandemic on the veterinary sector. In 2021, the market recorded increased demand and sale of veterinary medicines, including orthopedic medicines. In 2022, other macroeconomic uncertainties, such as global recession and cost inflation, adversely impacted the business. However, as the underlying market drivers remain unchanged owing to an increasing prevalence of orthopedic disorders in dogs and horses, the market is estimated to grow notably over the forecast period.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/us-veterinary-orthopedic-medicine-market-report

U.S. Veterinary Orthopedic Medicine Market Report Highlights

Based on product, pharmaceuticals segment dominated the market, accounting for a share of 46.72% in 2023. Pharmaceutical treatments for orthopedic diseases in pets, such as Non-steroidal Anti-inflammatory Drugs (NSAIDs) and pain relievers, have been widely used and established as effective treatments for managing pain and inflammation. On the other hand, the viscosupplements segment is anticipated to grow at the fastest CAGR of 8.23% during the forecast period

Based on animal type, the market is segmented into dogs and horses. The dogs segment dominated the market, accounting for a share of 51.98% in 2023. It is also anticipated to grow at the fastest CAGR of 7.80% in the coming decade

Based on application, the osteoarthritis segment accounted for the largest share of 60.65% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 9.39% over the forecast period

Based on route of administration, the market is segmented into injectable, oral, and others (e.g., topical). The injectable segment dominated the market, accounting for a share of 60.40% in 2023. The others (e.g., topical) segment is anticipated to grow at the fastest CAGR of 8.22% in the coming decade

On the basis of end-use, veterinary clinics & hospitals segment accounted for the largest share of 53.59% of the market in 2023. The other segment is expected to grow at the fastest CAGR of 8.68% over the forecast period

U.S. Veterinary Orthopedic Medicine Market Segmentation

Grand View Research has segmented the U.S. veterinary orthopedic medicine market based on product, animal type, application, route of administration, and end-use:

U.S. Veterinary Orthopedic Medicine Product Outlook (Revenue, USD Million, 2018 - 2030)

Biologics

Stem Cells

Platelet-Rich Plasma (PRP)

Other Biologics

Viscosupplements

Pharmaceuticals

Steroids

NSAIDS

Others

U.S. Veterinary Orthopedic Medicine Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

Dogs

Small Breeds

Medium Breeds

Large Breeds

Horses

U.S. Veterinary Orthopedic Medicine Application Outlook (Revenue, USD Million; 2018 - 2030)

Osteoarthritis

Degenerative Joint Disease

Others

U.S. Veterinary Orthopedic Medicine Route Of Administration Outlook (Revenue, USD Million, 2018 - 2030)

Injectable

Intra-Muscular

Intra-Articular

Others

Oral

Others

U.S. Veterinary Orthopedic Medicine End-use Outlook (Revenue, USD Million, 2018 - 2030)

Veterinary Hospitals & Clinics

At-home

Others

List of Key Players in the U.S. Veterinary Orthopedic Medicine Market

Zoetis Services LLC

Ardent Animal Health, LLC

Enso Discoveries

VetStem, Inc.

Contura Vet

PetVivo Holdings, Inc.

T-Cyte Therepeutics

Boehringer Ingelheim International GmbH

Arthrex, Inc.

MEDREGO LLC

Nucleus ProVets

Daiichi Sankyo Company, Limited 

Bimeda U.S.

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/us-veterinary-orthopedic-medicine-market-report

[bhushans]

Global Over-The-Counter Pain Medication Market : A Deep Dive into Key Drivers and Trends

The global over-the-counter pain medication market is expected to grow rapidly, reaching a valuation of US$ 35,090.10 million by 2034. This increased trend is anticipated to be accelerated by an increase in the number of seniors and a growing consumer demand for better pain treatment choices.

Many consumers are turning to generic drugs in an effort to reduce their overall spending on over-the-counter (OTC) or non-prescription painkillers. To ensure the effectiveness and safety of over-the-counter medications, a number of regulatory bodies, including the US Food and Drug Administration (FDA), have established stringent criteria and labeling requirements.

Preview Next-Level Insights Sample : https://www.futuremarketinsights.com/reports/sample/rep-gb-8947

According to the report, acetaminophens are among the most often bought over-the-counter pain relievers, accounting for 45% of the market for these medications. According to the FMI report, demand for acetaminophen will stay strong in the future years due to its reputation as a safer pain reliever than other medications.

A recent study on the abuse of over-the-counter combination medications containing acetaminophen was released by the American trade body Consumer Healthcare medications body (CHPA). According to the study, exposures related to therapeutic abuse of over-the-counter combo medications including acetaminophen decreased by 28%.

Competitive Analysis:

Crucial suppliers of over-the-counter painkillers dominate much of the competitive environment in the market, stimulating innovation and changing the dynamics of the industry. Prominent manufacturers of over-the-counter pain relievers include Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., and GlaxoSmithKline plc.

To remain at the top of their respective marketplaces, take advantage of their diverse portfolios and worldwide connections. Bristo-Meyers Squibb and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co., and Cardinal Health Inc. are all significant players in this competitive over-the-counter pain medication industry, and each brings unique strategies and strengths to the fore.

These suppliers of over-the-counter painkillers employ a range of tactics, such as forceful advertising campaigns, business partnerships, and unique product offerings, to differentiate themselves from rivals and increase their market share. Constant efforts are made to enhance the convenience, safety, and efficacy of products in order to satisfy the diverse needs and preferences of consumers.

Distribution networks, brand recognition, and regulatory compliance are important variables influencing the strength of the over-the-counter painkiller business. Businesses devote a large amount of money on R&D, quality assurance, and customer service in order to maintain a competitive advantage and encourage sustainable growth.

Our Methodology Overview: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-8947

Pivotal Over-the-Counter (OTC) Pain Medication Vendors:

Pfizer Inc.

Johnson & Johnson Services Inc.

Bayer AG

Sanofi S.A.

GlaxoSmithKline plc.

Bristo-Meyers Squibb and Company

Teva Pharmaceutical Industries Ltd.

Mylan N.V.

Merck & Co.

Cardinal Health Inc.

Key Segments:

By Drug Class:

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Local Anaesthetics

Acetaminophen

By Route of Administration:

Oral

Topical

Others

By Dosage Form:

Tablets

Capsules

Creams

Gels

Others

By Distribution Channel:

Hospital Pharmacies

Drug Stores

Retail Stores

E-commerce

Others

By Region:

North America

Latin America

Europe

East Asia

South Asia and Pacific

Middle East and Africa (MEA)

[bizworldinsights]

Muscle and Joint Pain Remedies Market

The global market for remedies addressing muscle and joint pain is projected to reach a valuation exceeding XX million in 2020, with an anticipated Compound Annual Growth Rate (CAGR) of over 6.9% from 2019 to 2025, ultimately achieving a market size of US$ XX million by 2025. Muscle and joint pain afflict a substantial portion of the mid-aged and geriatric population, with severe discomfort resulting from tendon and ligament stretches caused by improper posture. A sedentary lifestyle, particularly prevalent in developed regions, is a significant contributing factor to the prevalence of muscle and joint pain.

Global Market Analysis – Muscle and Joint Pain Remedies

The 2020 report on the Muscle and Joint Pain Remedies market provides a comprehensive analysis based on therapeutic application, prescription type, product formulation, and distribution channels.

Product Types:

Non-Opioids

Non-steroidal Anti-Inflammatory Drugs (NSAIDs)

Methyl Salicylate

Capsaicin

Lidocaine

Opioids

Buprenorphine

Fentanyl

Prescription Types:

Prescription

Over-the-Counter (OTC)

Formulations:

Cream

Gels

Spray

Patch

Others

Distribution Channels:

Pharmacies

Online Channels

Hypermarket & Supermarkets

Convenience Stores

Drug Stores

Hospitals

Others

Global Market Size Analysis – Regional Overview

North America emerged as the dominant region globally, accounting for a 36.9% share in 2019. The Asia Pacific region is projected to experience the fastest CAGR during the forecast period, with China and India identified as lucrative markets.

Competition Analysis – Key Players in the Muscle and Joint Pain Remedies Market

Leading companies in the industry include Reckitt Benckiser Group Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson, Novartis AG, Sanofi S.A., Topical BioMedics, Inc., Chattem, Inc., Exzell Pharma, AdvaCare Pharma, Sun Pharmaceutical Industries Ltd., Performance Health Technologies, Inc., and Nestle.

COVID-19 Impact on the Global Muscle and Joint Pain Remedies Market

Projections suggest a 23.5% decline in industry sales in 2020 compared to 2019. For a detailed understanding of the short-term and long-term impacts of COVID-19 on the market, consult with Bekryl Analysts.

[nitasonwane]

Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Forecast to 2027

The prevalence of chronic pain imposes a significant health and economic burden due to reduced productivity and treatment expenses. Non-steroidal anti-inflammatory drugs (NSAIDs) are the primary choice for alleviating pain and inflammation. The increasing incidence of conditions like rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, and migraines is driving the demand for these medications. They have become the most widely prescribed drugs worldwide, with approximately 84 million NSAID prescriptions issued annually in the U.S., as stated in a press release by Endo International plc.

Here are some key points about the NSAIDs market as of 2021:

Market Size and Growth: The global NSAIDs market was valued in the billions of US dollars. The market was expected to continue growing, driven by factors such as an aging population, an increasing incidence of chronic diseases, and a rising awareness of the benefits of NSAIDs.

Types of NSAIDs: The market includes various types of NSAIDs, such as ibuprofen, naproxen, aspirin, diclofenac, and others. Each type has specific indications and varying levels of market share.

Indications: NSAIDs are used primarily to manage pain, inflammation, and fever. They find applications in various medical conditions like arthritis, headaches, menstrual cramps, and musculoskeletal injuries.

Prescription vs. Over-the-Counter (OTC): Some NSAIDs are available over-the-counter, while others require a prescription. OTC NSAIDs are widely used for mild to moderate pain relief, while prescription NSAIDs are often used for more severe conditions.

Distribution Channels: NSAIDs are distributed through various channels, including hospitals, pharmacies, online retail, and others. The choice of channel depends on factors like the type of NSAID, the severity of the condition, and regional preferences.

Regional Trends: The market for NSAIDs may vary significantly by region. Factors such as healthcare infrastructure, regulatory policies, and cultural preferences can influence market dynamics.

Competitive Landscape: The NSAIDs industry is competitive, with several pharmaceutical companies manufacturing and marketing these drugs. Some of the major players in the market include Pfizer, Bayer, Novartis, Johnson & Johnson, and GlaxoSmithKline, among others.

[healthcareanna]

Autoimmune Disease Treatment Market Report Insights, Global Strategies & Growth Factors

Autoimmune Disease Treatment Market Overview

Market Research Future (MRFR)’s latest assessment reveals that the global autoimmune disease treatment market share is expected to thrive at Steady CAGR during the forecast period. The market signifies massive unmet needs for diagnosis. It is projected to favor the expansion of the global market by bringing advanced, precise and effective drugs and treatments.

Definite causes for the development of autoimmune diseases have not been identified. Thus, the emphasis is on the early diagnosis of the disease. Increasing awareness coupled with large-scale prevalence is likely to aid the proliferation of the Autoimmune Disease Treatment Market Overview in the foreseeable future.

Expenditures for the treatment of these diseases are on the rise and is poised to exhibit a similar trend in the forthcoming years. As per the National Institutes of Health (NIH), the U.S., the healthcare expenditure for autoimmune diseases has reached half of that of the cancer expenditure. Furthermore, the introduction of favorable policies for insurance reimbursements are anticipated to augment the market over the next couple of years. However, factors such as side effects, counterfeit drugs, and expensiveness of the treatment are forecasted to check the expansion of the autoimmune disease treatment market across the review period.

Competitive Dashboard:

Autoimmune Disease Treatment MarketPlayers are Abbott Laboratories, Genentech Inc., Bayer Schering Pharma AG, Amgen Inc., Biogen Idec Inc., Chugai Pharmaceutical Co. Ltd., Danaher, Bio-Rad, Elan Corporation Plc, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Eli Lilly and Company, Johnson & Johnson Inc., Siemens, Squibb Company, Merck & Co. Inc., and Thermo Fisher Scientific.

Market Segmentation

By disease type, the global autoimmune disease treatment market has been segmented into localized, and systemic. The localized segment is further sub-segmented into multiple sclerosis, inflammatory bowel disease, diabetes, and other. The systemic segment is sub-segmented into rheumatoid arthritis, psoriasis, lupus, and others.

By diagnosis, the autoimmune disease treatment market outlook has been segmented into ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.

By therapeutic products, the market has been segmented into drugs and therapeutic and monitoring equipment. The drugs segment is further sub-segmented into biologics, immunosuppressant, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.

By distribution channel, the autoimmune disease treatment market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.

Regional Analysis

The autoimmune disease treatment market report spans across Asia Pacific, Americas, Europe, and the Middle East & Africa. Americas signifies a huge potential for growth owing to increasing patient population. In addition, the increase witnessed in the expenditures associated with medical facilities is prognosticated to favor the expansion of the market over the next couple of years. The region has been estimated to gain control over the largest share of market in the forthcoming years.

The government of Europe has extended firm support in favor of research & development in the healthcare sector. This, in turn, is likely to pave the way for the growth of the in the region. It is expected to place the region on the second spot globally over 2023.

Asia Pacific has unleashed immense opportunities in the market through rapid developments witnessed in the healthcare sector. The population has also created a positive influence on the growth of the market by increasing its healthcare expenditures.

Related reports-

Heart Transplant Market Research Report - Global Forecast till 2030

Bladder Cancer Market Research Report - Forecast to 2030

CBD Hemp Oil Market Research Report – Forecast to 2030

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[rohans18]

Autonomic Dysreflexia Treatment Market Size, Reports, Demands, Share - Forecast 2028

Global Autonomic Dysreflexia Treatment Market, By Injury Type (Complete Spinal Cord Injury, Incomplete Spinal Cord Injury), Drug Type (Corticosteroids, Muscle Relaxants and Anti-spastic Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAID’S), Anti-Depressants, Anticonvulsants, Others), Route of Administration (Oral, Intravenous), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

In the consistent Autonomic Dysreflexia Treatment market research report, industry trends are put together on macro level with which clients can figure out market landscape and possible future issues about Autonomic Dysreflexia Treatment industry. The scope of this market report include but is not limited to latest trends, market segmentation, new market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target market analysis, insights and innovation. The report presents with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. An influential Autonomic Dysreflexia Treatment market report brings precise and exact market research information that drives business into the right direction.

Key Players

The major players covered in the Autonomic Dysreflexia Treatment market report are BioHorizons IPH, Inc., Floss Locations, Dr. Fresh LLC, Colgate-Palmolive Company, GlaxoSmithKline plc, 3M Company, Ultradent Products Inc., Bausch Health Companies Inc., Dentsply Sirona, Medtronic PLC, Zimmer Biomet Inc., Sunstar Suisse S.A. and PatientPop.Inc among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-autonomic-dysreflexia-treatment-market

The research studies entailed in the winning Autonomic Dysreflexia Treatment market report supports to estimate several important aspects that includes but are not limited to investment in a rising market, success of a new product, and expansion of market share. The strategies underlined here mainly consist of new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others that boost footprints in this market. Several other factors such as import, export, gross margin, price, cost, and consumption are also analyzed under the section of production, supply, sales and market status.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Autonomic Dysreflexia Treatment Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

[the-rachana]

Kyphoscoliosis Therapeutics Market to hit US$ 4.49 by 2031: Growth Plus Reports

Newark, New Castle, USA - Kyphoscoliosis Therapeutics Market Analysis 2023 | Business Opportunities, Pricing Strategy, Forthcoming opportunities planning, Market-specific challenges, Globally Market Key Facts are coverd in this report by Growth Plus Reports | 100+ Report Pages

Kyphoscoliosis Therapeutics Market 2023 with 100+ Pages Report and enhance with extents shares into sub-counties are covered in this market. Kyphoscoliosis Therapeutics Market conditions can be influenced by a wide range of factors, including economic policies, geopolitical events, and technological developments.

Browse Market Size, charts, tables and figures extent in-depth TOC with 100+ Report Pages on Kyphoscoliosis Therapeutics Market, Business Outlook, Top Companies, Key Regions, Product Demand, Market Size and Growth.

Get a Sample PDF of Report at: https://www.growthplusreports.com/inquiry/request-sample/kyphoscoliosis-therapeutics-market/8751

SEGMENTATION

GLOBAL KYPHOSCOLIOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DRUG TYPE

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Muscle Relaxants

Others

GLOBAL KYPHOSCOLIOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY TYPE

Postural Kyphosis

Scheuermann's Kyphosis

Congenital Kyphosis

GLOBAL KYPHOSCOLIOSIS THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Kyphoscoliosis Therapeutics market focuses on analyzing the current competitive situation in the Kyphoscoliosis Therapeutics market and provides basic information, market data, product introductions, etc. of leading companies in the industry. At the same time, includes the highlighted analysis-Strategies for Company to Deal with the Impact of COVID-19, It may also be helpful to consult with a financial who can provide direction based on your specific financial situation and goals.

Top Key Players of the Market:

Amneal Pharmaceuticals LLC

Johnson and Johnson

Perrigo Company plc

Teva Pharmaceutical Industries Ltd.

Aurobindo Pharma Limited

Pfizer Inc.

Bayer AG

Viatris Inc.

Merck & Co., Inc.

GSK Plc

Get your Customized Report here: https://www.growthplusreports.com/inquiry/customization/kyphoscoliosis-therapeutics-market/8751

Kyphoscoliosis Therapeutics Market TOC: https://www.growthplusreports.com/report/toc/kyphoscoliosis-therapeutics-market/8751

COVID-19 has had a significant impact on many industries. The pandemic has disrupted global supply chains, leading to shortages of certain goods and materials. It has also resulted in decreased demand for some products and services, as people have been staying home more and spending less money on non-essential items. Many businesses have had to close temporarily or permanently due to lockdowns and social distancing measures. Some industries, such as healthcare, online retail, and delivery services, have seen an increase in demand as a result of the pandemic. Overall, the COVID-19 pandemic has had a significant and far-reaching impact on the global economy.

Market segment by Region/Country including: -

-North America (United States, Canada and Mexico)

-Europe (Germany, UK, France, Italy, Russia and Spain etc.)

-Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

-South America (Brazil, Argentina and Colombia etc.)

-Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

Key takeaways from the Kyphoscoliosis Therapeutics market report:

Detailed considerate of Kyphoscoliosis Therapeutics market-particular drivers, Trends, constraints, Restraints, Opportunities and major micro markets.

Comprehensive valuation of all prospects and threat in the In depth study of industry strategies for growth of the Kyphoscoliosis Therapeutics market-leading players.

Kyphoscoliosis Therapeutics market latest innovations and major procedures.

Favorable dip inside Vigorous high-tech and market latest trends remarkable the Market.

Conclusive study about the growth conspiracy of Kyphoscoliosis Therapeutics market for forthcoming years.

Directly Purchase this premium report now at flat 20% discount: https://www.growthplusreports.com/checkout-8751

Visit our report store at - https://www.growthplusreports.com/report-store

Manan Sethi

Director, Market Insights

Email: sales@growthplusreports.com

256 Chapman Road

STE 105-4, Newark,

New Castle - 19702, USA

Phone no: +1 888 550 5009

Web: https://www.growthplusreports.com/

About us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020."

[neha24blog]

Non-steroidal Anti-inflammatory Drugs Market In-Depth Research On Basis Of Disease Indication, Route Of Administration, Distribution Channel, Region And Forecast To 2030  : Grand View Research Inc.

Non-steroidal Anti-inflammatory Drugs Market In-Depth Research On Basis Of Disease Indication, Route Of Administration, Distribution Channel, Region And Forecast To 2030  : Grand View Research Inc.

San Francisco, 27 Sep 2022: The Report Non-steroidal Anti-inflammatory Drugs Market Size, Share & Trends Analysis Report By Disease Indication (Arthritis, Migraine, Ophthalmic Diseases), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 – 2030 The global non-steroidal anti-inflammatory drugs market is expected to reach USD 31.29 billion by 2030,…

[maxsmith059]

Global Periodic Fever Syndrome Market to be Driven by Increasing Investments in the Research and Development Activities in the Forecast Period of 2021-2026 | ExpertMarketResearch.Com

The new report by Expert Market Research titled, ‘Global Periodic Fever Syndrome Market Report and Forecast 2021-2026’, gives an in-depth analysis of the global periodic fever syndrome market, assessing the market based on its segments like treatments, indications, routes of administration, distribution channels, end uses, and major regions. The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analyzing the market based on the SWOT and Porter’s Five Forces models.

Note 1: For a snapshot of the primary and secondary data of the market (2015-2025), along with business strategies and detailed market segmentation, please click on the request sample report. The sample report shall be delivered to you within 24 hours.

Request a free sample copy in PDF or view the report summary@ https://www.expertmarketresearch.com/reports/periodic-fever-syndrome-market/requestsample

The key highlights of the report include:

Market Overview (2016-2026)

The global periodic fever syndrome market would have a positive outlook in the forecast period due to robust investments in the research and development in the developing medicines. The American College of Rheumatology provides education and support for children and families living with periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA), which is expected aid the market growth in the coming years.

Industry Definition and Major Segments

A periodic fever syndrome is a group of disorders in which a person experiences recurrent episode of fever over time, usually accompanied by the same symptoms. Each episode of fever usually lasts roughly the same length of time. These disorders are very rare genetic conditions. Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is the most common type of periodic fever syndrome. Other common types include familial Mediterranean fever (FMF).

Explore the full report with the table of contents@ https://www.expertmarketresearch.com/reports/periodic-fever-syndrome-market

The market on the basis of treatment can be divided into:

Oral Anti-Inflammatory Drugs

Non-Steroidal Anti-Inflammatory Drugs

Anti-TNF Therapy

Statins

Others

On the basis of indication, the market is divided into:

Hyperimmunoglobulinemia D Syndrome

Familial Mediterranean Fever

TNF Receptor-Associated Periodic Syndrome

Cryopyrin-Associated Periodic Syndrome

Others

The routes of administration can be divided into:

Oral

Injections

Others

The distribution channels can be categorised as follows:

Hospital Pharmacy

Retail Pharmacy

Online

Others

On the basis of end use, the industry can be categorized into:

Hospitals

Speciality Centres

Others

Read Latest Reports on Periodic Fever Syndrome@ https://www.expertmarketresearch.com/pressrelease/global-periodic-fever-syndrome-market

The regional markets for the product can be divided as follows:

1 North America 1.1 United States of America 1.2 Canada 2 Europe 2.1 Germany 2.2 United Kingdom 2.3 France 2.4 Italy 2.5 Others 3 Asia Pacific 3.1 China 3.2 Japan 3.3 India 3.4 ASEAN 3.5 Others 4 Latin America 4.1 Brazil 4.2 Argentina 4.3 Mexico 4.4 Others 5 Middle East & Africa 5.1 Saudi Arabia 5.2 United Arab Emirates 5.3 Nigeria 5.4 South Africa 5.5 Others

Market Trends

The rising funding from healthcare organisations into the treatment of this syndrome is expected to propel the market growth in the coming years. NHS England has funded a ‘life-changing treatment’ for individuals with periodic fever syndromes. NHS, the public health system of England, is working in collaboration with Novartis to help reduce the frequency of flares in children and adults with the syndrome through the use of the immunomodulatory drug canakinumab (Ilaris). Such developments and programmes are expected to promote the growth of the market in the coming years.

Key Market Players

The major players in the market are Swedish Orphan Biovitrum AB, Novartis AG, and Texas Allergy Group, PLLC, among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

Related Reports:

Global Medical Wellness Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/348nb30

Global Galvanic Skin Response Sensor Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/2KkNBYk

Global Ascites Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/37gfSsc

Global Cleanroom Technology Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/37hvawJ

Global Umbilical Cord Blood Banking Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/3gOjh4r

Global Pulmonary Artery Catheter Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/2W9uS4C

Global Cranial Electrotherapy Stimulation Devices Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/3qUZhly

Global Anoscope Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/37l2tPH

Global External Ventricular Drain Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/3mbdEOU

Global Nasal Aspirators Market Report and Forecast 2021-2026 by Expert Market Research: https://bit.ly/34aCJDu

Note 2: As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

About Us:

Expert Market Research is a leading business intelligence firm, providing custom and syndicated market reports along with consultancy services for our clients. We serve a wide client base ranging from Fortune 1000 companies to small and medium enterprises. Our reports cover over 100 industries across established and emerging markets researched by our skilled analysts who track the latest economic, demographic, trade and market data globally.

At Expert Market Research, we tailor our approach according to our clients’ needs and preferences, providing them with valuable, actionable and up-to-date insights into the market, thus, helping them realize their optimum growth potential. We offer market intelligence across a range of industry verticals which include Pharmaceuticals, Food and Beverage, Technology, Retail, Chemical and Materials, Energy and Mining, Packaging and Agriculture.

We also provide state-of-the-art procurement intelligence through our platform, https://www.procurementresource.com. Procurement Resource is a leading platform for digital procurement solutions, offering daily price tracking, market intelligence, supply chain intelligence, procurement analytics, and category insights through our thoroughly researched and infallible market reports, production cost reports, price analysis, and benchmarking.

Informes de Expertos (https://informesdeexpertos.com), the Spanish variant of Expert Market Research, is a platform that offers market research and consultancy services to a broad clientele base across Spanish-speaking countries. With our primary focus on the Latin America and Spain markets, our research experts provide relevant and actionable insights into the markets and track major trends, economic developments, and global trade data.

Determined to bring client satisfaction, we make sure that our tailored approach meets the client’s unique market intelligence requirements. Our syndicated and customized research reports cover a wide spectrum of industries ranging from pharmaceuticals and food and beverage to packaging, logistics, and transportation.

Contact Information: Company Name: Expert Market Research Contact Person: Max Smith, Corporate Sales Specialist – U.S.A. Email: sales@expertmarketresearch.com Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790 Address: 30 North Gould Street, Sheridan, WY 82801, USA City: Sheridan State: Wyoming Country: United States Website: https://www.expertmarketresearch.com

[aprao22]

Top 10 Pharma companies

Top 10 pharmaceutical companies in the world

These are ranked by revenue and market capitalization:

1. Pfizer — $51.8 billion 2. Roche  — $50.1 billion 3. Novartis  — $47.45 billion                                                                                    4. Merck  — $46.9 billion 5. GlaxoSmithKline (GSK) — $43.6 billion 6. Johnson & Johnson (J&J) — $42.2 billion 7. AbbVie — $33.3 billion 8. Sanofi — $27.8 billion 9. Bristol-Myers Squibb — $26.2billion 10. AstraZeneca — $23.6 billion

1.Pfizer

Pfizer is an American multinational pharmaceutical corporation, headquartered in Manhattan. It develops and produces medicines and vaccines for a wide range including oncology, cardiology, neurology, immunology, and endocrinolog

2.Roche

Hoffmann-Roche AG is a Swiss multinational pharmaceutical company headquarters located in Basel, Switzerland.it operates two divisions: Pharmaceuticals and Diagnostics.

3.Novartis

Novartis AG is a Switzerland multinational pharmaceutical company headquarters located in Basel. It manufactures drugs clozapine, diclofenac, carbamazepine, valsartan, terbinafine, and others.

4.Merck

Merck & Co. is a German multinational pharmaceutical company incorporated in Jersey, United States of America.

5. GlaxoSmithKline ( GSK)

GlaxoSmithKline (GSK) is a British multinational pharmaceutical company headquartered in Brantford, England in 2000.

6. Johnson & Johnson (J&J)

Johnson & Johnson (J&J) is an American multinational company headquartered, New Jersey in 1886. It develops medical devices, pharmaceuticals, and consumer goods.

7. AbbVie

AbbVie is an American multinational corporation biopharmaceutical company founded in 2013. It operates as research-based pharmaceutical products, medical devices, diagnostic equipment, and nutrition products

8. Sanofi

Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris, France, founded in 2013. It operates in the R&D, manufacturing, and pharmaceutical drugs' major therapeutic areas are the cardiovascular, central nervous system, diabetes, internal medicine, oncology, and vaccines.

9. Bristol-Myers Squibb

Bristol Myers Squibb is an American multinational pharmaceutical company, located in New York City. It manufactures pharmaceuticals, biologics, therapeutics, oncology, HIV, cardiovascular, diabetes, hepatitis, arthritis, and psychiatric diseases.

10. AstraZeneca 

AstraZeneca, is a Britain-Swedan multinational biopharmaceutical company, headquarters in England. It has manufactured major disease areas cancer, cardiovascular, respiratory, and inflammation. In 1999. they merged Swedish Astra AB and the British Zeneca Group.

Top 10 pharmaceutical companies in India

The top 10 pharmaceutical companies in India ranked by revenue and market capitalization:

Rank    Industry                        $Billions        ₹Crores

1           Sun Pharma                   10.3              75326.63

2           Dr. Reddy’s                      7.4               54,223.62

3           Divi’s                                6.2               45,023.67

4          Cipla                                 5.3               38,875.43

5          Aurobindo                         4.9               35,641.85

6          Torrent                              4.4               32054.46

7          Lupin                                 4.2               30362.52

8          Zydus Cadila                     3.5               25325.64

9          Abbott India                       3.1               22624.21

10        Alkem                                2.5                18584.54

India is the largest provider of generic medicines, holding a market share of 25% to worldwide supply by volume and meets 61% of the vaccine requirement around the world. Indian pharmaceutical companies also supply 81% of antiretroviral medications (HIV/AIDS) in the worldwide markets.

The international pharmaceutical market is anticipated to surpass USD 1.2Trillion by 2022. India is one most suitable states in this worldwide pharma market. India provides more than 55% of the worldwide purpose for different vaccines and 45% of the demand for generic medicines in the United States. India’s pharmaceuticals demanded to expand at 11% CAGR during 2023 to reach 33 Billion US dollars.

1. Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd is an Indian multinational pharmaceutical company founder Dilip Shanghvi in 1983, Vapi, Headquarters Goregaon, Mumbai, India, And Subsidiaries Ranbaxy Laboratories, etc...It produces and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India also the United States. Sun Pharma provides formulations in psychiatry, cardiology, dialectology, neurology, and gastroenterology. The company supplies APIs such as etodolac, clorazepate, carbamazepine, warfarin, and anti-cancer drugs, peptides, steroids, sex hormones, etc. Sun supplies more than 2000 formulations and also exports in various other countries. The main features of Sun Pharmaceuticals are research and development facilities and its own API’s

2. Dr. Reddy’s Laboratories Ltd

Dr. Reddy’s Laboratories Ltd is an Indian multinational pharmaceutical company founder Kallam Anji Reddy in 1984, Hyderabad, India. The company produces pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and other countries and more than 195 drugs, 65 APIs for drug, biotechnology products. DRL has six APIs(CTO)and four Formulations(FTO)manufacturing plants across India. Its main focus research and development centers are Integrated product development Organization(IPDO) and Custom Pharmaceutical Services(CPS) located in Hyderabad, India.

3.Divi’s Laboratories Ltd

Divis Laboratories Ltd is an Indian pharmaceutical company founder Murali Divi in 1990, Hyderabad, India. It manufactures APIs, Intermediates, and Nutraceutical ingredients. Divis Labs have three manufacturing units located at Chouttal, Hyderabad, Chippada, A. Andhra Pradesh, and 3 Research and development centers. The Company exports the products to the USA, Europe, Japan, South Africa, Australia, and the Philippines.

4. Cipla Ltd

Cipla is an Indian multinational pharmaceutical company founder Khwaja Abdul Hamied in 1935, Headquarters Mumbai, India, And supplies top-quality generic medicines in India The company supplies a wide range of medicines. It has got a prominent position in the Indian market ad global market and more than 150 countries. The company provides quality products worldwide received approvals from major regulatory agencies and more than 2000 formulations cover areas like neurology and nephrology. Cipla has a global focus on the important markets of India, the US, and South Africa.

5.Aurobindo Pharma Ltd

Aurobindo Pharma is an Indian pharmaceutical company founder Nityananda Reddy started operations in 1988 with a single unit manufacturing Synthetic Penicillin at Pondicherry after became a public company in 1992 headquartered in HITEC City, Hyderabad, India. the company has provided key therapeutics like cardiovascular, antiretrovirals, antibiotics, gastroenterology, anti-diabetics, anti-Allergics. The company exports products to more than 160 nations in the world. Aurobindo pharma has production, research, and development and Subsidiaries units are Novagen Pharma, AuroZymes Ltd, etc

6. Torrent Pharmaceuticals Ltd

Torrent Pharma an Indian pharmaceutical company founder Uttambhai NathalalMehta in 1959 Headquarters Ahmedabad, India. started as Trinity Laboratories Ltd, and renamed Torrent Pharmaceuticals Ltd. nowadays, it is ranked leaders in the therapeutic sector of the women’s health care, cardiovascular, CNS, gastrointestinal, diabetology, oncology, gynecology, and anti-infective. They have first-class manufacturing units, R & D facilities, and a prevalent international presence in more than 50 nations. The company had procured the Elder Pharma’s Indian company, Zyg Pharma, the API plant of Glochem Industries, Unichem’s Sikkim Plant, Bio-Pharm Inc, generic pharmaceuticals, etc.

7. Lupin Ltd

Lupin is a multinational pharmaceutical company founder Desh Bandhu Gupta in 1968 Mumbai, India a large range of products like Branded & Generic Formulations, Biotechnology Products, APIs, and manufacturing centers are across India, Japan, Brazil, Mexico, and the United States. Subsidiaries are Novel Laboratories, Polynova Industries, and GAVIS Pharmaceuticals. The company is in treatment areas of Non-Steroidal Anti-Inflammatory Drugs, Cardiovascular, Gynaecology, Asthma, Paediatric, Diabetology, Gastro-Intestinal, and Anti-Infective drugs, Anti-TB and Cephalosporins sectors. The company is moved around more than 100 countries. It supplies top quality medications.

8.Zydus Cadila Healthcare Ltd

Zydus Cadila is a Zydus Cadila, is a fully integrated Indian Pharmaceutical company founded by Ramanbhai B. Patel in 1952 in Ahmedabad, Gujarat India. It provides active pharmaceutical ingredients, formulations, and animal healthcare products to wellness products. The company’s research and development facilities are in Gujarat, Maharashtra, Goa, Himachal, and Sikkim also research units in the US and Brazil. It has 1400 researchers across 20 sites, working on medicines and exploring various ideas from NCEs to vaccines, bio-similar products. The company’s global business has regulated markets of the United States, Europe, South Africa, Latin America, and also 30 other national markets in the world.

9. Abbott Pharma India Ltd

Abbott India Limited is a Pharmaceutical company founder Dr. Wallace Calvin Abbott in 1944, Mumbai, India, and a subsidiary of Abbott Laboratories United States. It manufactures pharmaceutical drugs, therapeutics Women’s Health, Neurology, Thyroid, Gastroenterology, Anti-Infective, Diabetes, Urology, Pain, Vitamins, etc., and a plant at Verna, Goa. Abbott has to produce high-quality formulations, branded generic pharmaceuticals, diagnostics, medical devices, and nutrition.

10. Alkem Laboratories Ltd

Alkem Laboratories is a Pharmaceutical company founder Samprada Singh in 1973, Mumbai, India. It provides quality branded generics, generic medications, APIs, nutraceuticals in India, and more than 60 countries around the world. Alkem Laboratories has been ranked as the No.1 Anti-infective company in India for more than ten years also therapeutic segments of gastrointestinal, Vitamins, Minerals, Nutrients, and pain management.

[bhushans]

A Market on the Move: Exploring Investment Opportunities in Global Painkillers Market

the global painkillers market growth is anticipated to be valued at US$ 100.9 billion by the end of 2033 and US$ 70.0 billion by the end of 2023. According to a new projection by Future Market Insights, opioids will command the highest price on the global market in 2022, with a share of roughly 53.4%. The regulatory landscape surrounding painkillers has a significant effect on the growth of the industry. These regulations are required to safeguard patient safety and prevent the misuse and overuse of painkillers, but if there are too many of them, people may not be able to get the right pain treatment.

Get a Sample Copy of the Report : https://www.futuremarketinsights.com/reports/sample/rep-gb-17075

Increased attention in recent years has led to stricter controls and prohibitions on the use of opiate painkillers. This has created an opportunity for non-narcotic painkillers, such as NSAIDs (non-steroidal anti-inflammatory pharmaceuticals), and other non-narcotic medications, to gain market share. Alternative pain management solutions could be offered by businesses in response to regulatory efforts to improve pain management and reduce opioid abuse, such as physician education initiatives and prescription drug monitoring systems. A number of leading pharmaceutical companies consistently prioritize clinical breakthroughs in the formulation and administration of analgesic drugs. They are also developing safer opioids that effectively manage pain and have fewer adverse effects.

The creation of analgesic formulations with abuse-deterrent qualities that are more challenging to manipulate for snorting or injection — the methods of administration most frequently associated with addiction due to their rewarding effects — is perhaps the most notable clinical improvement.

Key Players:

AbbVie Inc. (Allergan plc)

Bristol Myers Squibb Co.

Sanofi S.A.

Boehringer Ingelheim International GmbH

Pfizer Inc.

Zydus Lifesciences Ltd. (Cadila Pharmaceuticals)

GSK plc.

Others

Key Market Segments Covered in Painkillers Industry Research

By Drug Class:

Opioids

Tramadol

Oxycodone

Hydrocodone

Other Opioids

NSAIDs

Local Anesthetics

Acetaminophen

By Product:

OTC Products

Prescription Drugs

By Indication:

Surgical Pain

Cancer Pain

Neuropathic Pain

Musculoskeletal and Joint Pain

Others

By Route of Administration:

Injectable

Oral

Rectal

Topical

Transdermal

Others

By Distribution Channel:

Hospital Pharmacies

Specialty Clinics

Long-Term Care Centers

Retail Pharmacies

Drug Stores

Online Pharmacies